Vir Biotechnology, Inc. VIR Business Segments — SG&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s business segments — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s business segments — SG&A?
- Vir Biotechnology, Inc. (VIR) reported business segments — SG&A of $23.34M in Q1 2026.
- How has Vir Biotechnology, Inc.'s business segments — SG&A changed year-over-year?
- Vir Biotechnology, Inc.'s business segments — SG&A decreased by 2.5% year-over-year, from $23.94M to $23.34M.
- What is the long-term trend for Vir Biotechnology, Inc.'s business segments — SG&A?
- Over 2 years (2022 to 2025), Vir Biotechnology, Inc.'s business segments — SG&A has grown at a -24.6% compound annual growth rate (CAGR), from $161.76M to $92.07M.
- What does business segments — SG&A mean?
- Represents the overhead costs associated with the segment's administrative functions, legal, finance, and general corporate support. This metric is used to evaluate the operational efficiency and the cost structure of the business segment's non-research activities.